Rezipres® (ephedrine hydrochloride) is now available for the treatment of clinically important hypotension occurring in the setting of anesthesia.

Rezipres 4.7mg/mL is a ready-to-use formulation of injectable ephedrine hydrochloride, an alpha- and beta-adrenergic agonist and a norepinephrine-releasing agent. Ephedrine stimulates heart rate and cardiac output and variably increases peripheral resistance, resulting in increased blood pressure.

“The availability of Rezipres will provide hospitals with an FDA-approved, ready-to-use ephedrine injection product as an alternative to compounded formats which are not approved by the FDA,” said Sean Brynjelsen, CEO of Eton Pharmaceuticals.

The premixed formulation of Rezipres is supplied as a single-dose 5mL ampule containing 4.7mg/mL solution of ephedrine hydrochloride (each mL equivalent to 3.8mg ephedrine base). The product is available for ordering through wholesalers McKesson, AmerisourceBergen, and Cardinal Health.

References

  1. Eton Pharmaceuticals and XGen Pharmaceuticals DJB announce commercial launch of Rezipres® (ephedrine hydrochloride), a ready-to-use formulation of injectable ephedrine (4.7 mg/mL). News release. Eton Pharmaceuticals, Inc. Accessed March 14, 2022. https://www.globenewswire.com/news-release/2022/03/14/2402427/0/en/Eton-Pharmaceuticals-and-XGen-Pharmaceuticals-DJB-Announce-Commercial-Launch-of-Rezipres-ephedrine-hydrochloride-a-Ready-to-Use-Formulation-of-Injectable-Ephedrine-4-7-mg-mL.html
  2. Rezipres. Package insert. Eton Pharmaceuticals, Inc.; 2022. Accessed March 14, 2022. https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/213536s000lbl.pdf